Piramal Alternatives concludes investment in Biodeal Pharmaceuticals

Piramal Alternatives successfully exits its ₹110 crore investment in Biodeal Pharmaceuticals, achieving over 20% returns through significant revenue growth.

Raccontata dathehindubusinessline.com